Should I buy, hold, or sell GTBP stock right now?

GT Biopharma Inc. (GTBP) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is GTBP's 12-month price target and RQD AI Jury consensus?

GTBP's 12-month base price target is $4.62 (range $3.6 to $22.71), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / GTBP

LSTA (29) GDTC (52) TVRD (32) ASBP (40) ⌘ Pro Terminal →

GT Biopharma Inc. (GTBP) — RQD Stock Rating Cockpit

$5.13 -3.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.09

GT Biopharma Inc. (GTBP) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $11.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GTBP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GTBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, GT Biopharma Inc. (NASDAQ: GTBP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.13 (-3.57% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, GTBP ranks #578 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GTBP compare to LSTA and GDTC in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GTBP carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LSTA (Lisata Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, GTBP leads on earnings multiple (N/A) while GTBP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GTBP?

▼

Per GTBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000109657), GT Biopharma Inc. generated $34.8M in revenue (-13.5% YoY), -$28.4M in net income, and -$12.9M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.09 (-0.83%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GTBP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY GTBP SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 42 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.50+12.5% Next Q

Q2 (-2Q)

Grade D$7.31-23.7% Next Q

Q3 (-1Q)

Grade E$5.58-8.1% Next Q

Current

Grade D-$5.13-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GTBP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GTBP currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.68) and Max Pain ($5.39) forces dealer call-delta covering toward $22.71.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GTBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GTBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE22% OF RANGE

L: $1$5.13H: $22

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on GTBP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (30)

8/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like GTBP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GTBP)

✓Walkthrough of GTBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GTBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.39%🛡️ HOLDING TREND SUPPORT

2026-11-03O $5.60H $5.60L $5.13C $5.13VOL 20.3K

RES: $10.77SUP: $5.10SMA50: $6.68SMA200: $9.62

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GTBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GTBP Butterfly Map → + Track GTBP →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -13.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GTBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GTBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GTBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GTBP)

Health Care Rank #578 of 1015 ⚔️ LSTA vs GTBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GTBP vs. LSTA, GDTC, TVRD, ASBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, GT Biopharma Inc. (GTBP) ranks #578 by composite RQD confidence (36/100, grade D-) and #885 by equity capitalization ($11.0M). Within this direct 5-issuer industry benchmark cohort, GTBP leads on earnings valuation at N/A trailing P/E, while GTBP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with GTBP at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GTBP ACTIVE GT Biopharma Inc.	D-	36/100	—	—	-35.0%	-3.57%	$11.0M	Benchmark Subject
LSTA Lisata Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.98%	$11.0M	/lsta-vs-gtbp →
GDTC CytoMed Therapeutics Limited	D+	52/100	—	—	—	-0.98%	$10.9M	/gdtc-vs-gtbp →
TVRD Tvardi Therapeutics Inc.	E	32/100	—	—	-35.0%	+1.58%	$10.6M	/tvrd-vs-gtbp →
ASBP Aspire-Lakewood Holdings Inc.	D-	40/100	—	-1.9%	-35.0%	-9.99%	$11.4M	/asbp-vs-gtbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000109657 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GT Biopharma Inc. (GTBP) reported GAAP revenue of $34.8M (-13.5% vs. FY2024 revenue of $40.2M , and -8.5% cumulative change since FY2023) , GAAP net income of -$28.4M, operating cash flow of -$12.9M, and free cash flow of -$12.9M (-0.1% YoY). On the balance sheet, GTBP closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$34.8M	-$28.4M	-$12.9M	-$12.9M	$8.1M	—
FY2024 (FY)	2024-12-31	$40.2M	-$13.2M	-$12.9M	-$12.9M	$4.2M	—
FY2023 (FY)	2023-12-31	$38.0M	-$7.6M	-$8.9M	-$8.9M	—	—

3. GTBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GTBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GTBP compare to LSTA and GDTC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GTBP?

Where is GTBP trading relative to its 50-day, 200-day, and 52-week technical levels?

GTBP last traded at $5.13 (-3.57% on volume of 33,602 shares), positioning the stock -23.20% below its 50-day simple moving average ($6.68) and -46.67% below its 200-day simple moving average ($9.62). Across its 52-week range of $0.54 to $21.63, GTBP sits at the 21.8% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.49 to $5.77).

Direct Sub-Reports: GTBP RQD Cockpit GTBP 12M Forecast GTBP Earnings & Move GTBP Dividends & DRIP GTBP Insiders & 13F GTBP Whale Options GTBP Profit Sankey GTBP News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

GTBP — GT Biopharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

GT Biopharma Inc. (GTBP) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $5.13 (-3.57% 1D, market capitalization $11.0M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

GT Biopharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The market capitalization is listed as $0.0B, which conflicts with the $11.5M figure in market data. Product, customer, and revenue-model details are — Reported revenue is — for each period in the SEC financials.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), GT Biopharma Inc. (GTBP) reported $34.8M in annual revenue (up from $40.2M in FY2024, -13.5% YoY) and -$28.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($38.0M revenue, -$7.6M net income) through FY2025, GTBP scaled operating cash flow to -$12.9M and free cash flow to -$12.9M, backed by $8.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.54 – $21.63 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies, no sector correlations, and no bottleneck links. Investors should monitor the company's own filings for any partner, supplier, or licensing relationships, which are not captured in the supplied data.

Key Question #1: Can GTBP sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $34.8M and free cash flow of -$12.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is GTBP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GTBP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for GT Biopharma Inc. (GTBP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GTBP Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 22h ago

Gt Biopharma Stock Price Forecast. Should You Buy GTBP?

StockInvest.us report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

GT Biopharma, Inc. SEC Filing (Oct 21, 2026) | GTBP EFFECT

Stock Titan report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Yahoo Finance report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A study on making pancreatic cancer more vulnerable to immune treatment gets an oral slot

Stock Titan report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Wednesday's Intraday Session - Pomdoctor (NASDAQ:POM), Stablecoin Develop

Benzinga report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

GlobeNewswire report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

AZR Stock Price and Chart — BOATS:AZR

TradingView report covering GT Biopharma Inc. (GTBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GTBP Bull vs. Bear Conversation Board — What's Your Call at $5.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GTBP 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $6.44 (+21.1%)

📌 Pinned Debate

Cash rose from $4.0M to $6.8M between FY 2024 and FY 2025 while the stock trades near its 52-week low of $0.54 after a $21.63 high, per

Cash rose from $4.0M to $6.8M between FY 2024 and FY 2025 while the stock trades near its 52-week low of $0.54 after a $21.63 high, per market data and SEC financials.. When you look under the hood at GTBP, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $21.63. My 12M target is $6.44.

SectorRotator 🐂 BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $4.31 (-19.0%)

Spot @ $5.32

Reported revenue is $0.0M in every period, net income was -$28.4M in FY 2025, and ROIC is -35% with a 0% FCF yield, per the SEC financi

Here is the bear case nobody on the bull side wants to address on GTBP: Reported revenue is $0.0M in every period, net income was -$28.4M in FY 2025, and ROIC is -35% with a 0% FCF yield, per the SEC financials and Roarable RQD rating.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.